An observational study in Non Small Cell Lung Cancer, sponsored by Jiangsu Cancer Institute & Hospital. Completed at 10 sites in China. Per ClinicalTrials.gov, last updated 2018-05-21.
Sponsored by Jiangsu Cancer Institute & Hospital · Observational
The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.
The trial is a multi-centre, real-world non-interventional observational study. In the study, the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were included via a retrospectively review method and the study data on patient demographic/tumor biological characteristics, and clinical treatments were collected to explore the clinical odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.
The eligible subjects are the Chinese T1 patients with non-small cell lung cancer complicated with lymph metastases
Exclusion Criteria:
Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
Procedure: Surgeries
Surgeries
Percentage of the patients with lymph metastases
Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics
Time frame: 2015 - 2017
Percentages of N0/N1/N2/N3 patients
Percentages of N0/N1/N2/N3 patients in the target population
Time frame: 2015 - 2017
Percentage of N2 patients with lymph nodes
Percentages of N2 patients with lymph nodes in N2 population
Time frame: 2015 - 2017
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
Time frame: 2015 - 2017
Number of lymph nodes in N2 patients
Number of lymph nodes in N2 patients categorised by tumor baseline characteristics
Time frame: 2015 - 2017
Percentage of patients with N2 skip metastases
Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics
Time frame: 2015 - 2017
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Cancer Institute & Hospital